[HTML][HTML] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - Elsevier
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
[引用][C] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - cir.nii.ac.jp
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe
plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial …
plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - infona.pl
Apremilast works intracellularly to regulate inflammatory mediators. ESTEEM 1 evaluated
efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis …
efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi… - Journal of the …, 2015 - scholars.northwestern.edu
Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective:
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi… - Journal of the …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the …, 2015 - europepmc.org
Objective ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for
moderate to severe plaque psoriasis. Methods This phase III, multicenter, double-blind …
moderate to severe plaque psoriasis. Methods This phase III, multicenter, double-blind …
[PDF][PDF] Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a …
K Papp, K Reich, CL Leonardi, L Kircik, RM Day… - 2015 - cyberleninka.org
Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective:
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - jaad.org
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial …
K Papp, K Reich, CL Leonardi… - Journal of the …, 2015 - research.manchester.ac.uk
BACKGROUND: Apremilast works intracellularly to regulate inflammatory mediators.
OBJECTIVE: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for …
OBJECTIVE: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for …
[PDF][PDF] Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a …
K Papp, K Reich, CL Leonardi, L Kircik, RM Day… - 2015 - core.ac.uk
Background: Apremilast works intracellularly to regulate inflammatory mediators. Objective:
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …